Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile

Infectious Agents and Cancer

Volumn 7, Issue 1, 2012, Pages

  Tang, Weihua ^a   Morgan, Douglas R ^a   Meyers, Michael O ^b   Dominguez, Ricardo L ^c   Martinez, Enrique ^d   Kakudo, Kennichi ^e   Kuan, Pei Fen ^f   Banet, Natalie ^a   Muallem, Hind ^a   Woodward, Kimberly ^a   Speck, Olga ^a   Gulley, Margaret L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Western Regional Hospital   (Honduras)

^d Department of Gastroenterology   (Honduras)

^e KOBE TOKIWA UNIVERSITY   (Japan)

^f IL   (United States)

Author keywords

Epstein barr virus; Gastric adenocarcinoma; Pharmacogenetic test; RNA expression profile; Stromal cells

Indexed keywords

CHROMOGRANIN; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; GASTRIN; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; OSTEONECTIN; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN FCER2; PROTEIN FSCN1; PROTEIN IFITM1; PROTEIN INHBA; PROTEIN MS4A1; PROTEIN PLUNC; PROTEIN TNFSF9; PUMA PROTEIN; SYNDECAN 1; THYMYDYLATE SYNTHASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VIRUS RNA;

ARTICLE; CELL METABOLISM; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INTERNALIZATION; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; STOMACH CANCER; UPREGULATION;

EID: 84865312299     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-7-21     Document Type: Article

References (95)

1. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
2. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, Int J Cancer 2010 127 2893 2917 10.1002/ijc.25516 21351269
3. Gastric carcinoma with lymphoid stroma: incidence of EBV and Helicobacter pylori infection. Cho HJ, Kim JY, Yoo J, Lee SS, Appl Immunohistochem Mol Morphol 2003 11 149 152 10.1097/00129039-200306000-00010 12777999 (Pubitemid 36749568)
4. Recurrent genomic aberrations in gastric carcinomas associated with Helicobacter pylori and Epstein-Barr virus. Chan WY, Liu Y, Li CY, Ng EK, Chow JH, Li KK, Chung SC, Diagn Mol Pathol 2002 11 127 134 10.1097/00019606- 200209000-00001 12218450
5. Association of Helicobacter pylori and Epstein-Barr virus with gastric cancer and peptic ulcer disease. Saxena A, Nath Prasad K, Chand Ghoshal U, Krishnani N, Roshan Bhagat M, Husain N, Scand J Gastroenterol 2008 43 669 674 10.1080/00365520801909660 18569983 (Pubitemid 351868704)
6. Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. Lee JH, Kim SH, Han SH, An JS, Lee ES, Kim YS, J Gastroenterol Hepatol 2009 24 354 365 10.1111/j.1440-1746. 2009.05775.x 19335785
7. Age-specific trends in incidence of noncardia gastric cancer in US adults. Anderson WF, Camargo MC, Fraumeni JF, Correa P, Rosenberg PS, Rabkin CS, JAMA 2010 303 1723 1728 10.1001/jama.2010.496 20442388
8. Divergent trends for gastric cancer incidence by anatomical subsite in US adults. Camargo MC, Anderson WF, King JB, Correa P, Thomas CC, Rosenberg PS, Eheman CR, Rabkin CS, Gut 2011 60 1644 1649 10.1136/gut.2010.236737 21613644
9. Histology-specific gender, age and tumor-location distributions of Epstein-Barr virus-associated gastric carcinoma in Japan. Koriyama C, Akiba S, Corvalan A, Carrascal E, Itoh T, Herrera-Goepfert R, Eizuru Y, Tokunaga M, Oncol Rep 2004 12 543 547 15289835
10. Epstein-barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with epstein-barr virus-negative carcinoma. Lee HS, Chang MS, Yang HK, Lee BL, Kim WH, Clin Cancer Res 2004 10 1698 1705 10.1158/1078-0432.CCR-1122-3 15014022 (Pubitemid 38435561)
11. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. van Beek J, zur Hausen A, Klein Kranenbarg E, van de Velde CJ, Middeldorp JM, van den Brule AJ, Meijer CJ, Bloemena E, J Clin Oncol 2004 22 664 670 10.1200/JCO.2004.08.061 14966089 (Pubitemid 41095069)
12. Association of Epstein-Barr virus with gastric carcinoma with lymphoid stroma. Oda K, Tamaru J, Takenouchi T, Mikata A, Nunomura M, Saitoh N, Sarashina H, Nakajima N, Am J Pathol 1993 143 1063 1071 8214002 (Pubitemid 24070549)
13. Epstein-Barr virus-associated gastric carcinomas: relation to H. pylori infection and genetic alterations. Wu MS, Shun CT, Wu CC, Hsu TY, Lin MT, Chang MC, Wang HP, Lin JT, Gastroenterology 2000 118 1031 1038 10.1016/S0016-5085(00) 70355-6 10833477
14. Loss of p16/CDKN2A tumor suppressor protein in gastric adenocarcinoma is associated with Epstein-Barr virus and anatomic location in the body of the stomach. Schneider BG, Gulley ML, Eagan P, Bravo JC, Mera R, Geradts J, Hum Pathol 2000 31 45 50 10.1016/S0046-8177(00)80197-5 10665912 (Pubitemid 30054386)
15. Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis. Camargo MC, Murphy G, Koriyama C, Pfeiffer RM, Kim WH, Herrera-Goepfert R, Corvalan AH, Carrascal E, Abdirad A, Anwar M, et al. Br J Cancer 2011 105 38 43 10.1038/bjc.2011.215 21654677
16. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Gravalos C, Gomez-Martin C, Rivera F, Ales I, Queralt B, Marquez A, Jimenez U, Alonso V, Garcia-Carbonero R, Sastre J, et al. Clin Transl Oncol 2011 13 179 184 10.1007/s12094-011-0637-6 21421462
17. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. Shah MA, Kelsen DP, J Natl Compr Canc Netw 2010 8 437 447 20410336
18. Newly emerging therapies targeting viral-related lymphomas. Ramos JC, Lossos IS, Curr Oncol Rep 2011 13 416 426 10.1007/s11912-011-0186-8 21792540
19. Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Song HJ, Srivastava A, Lee J, Kim YS, Kim KM, Ki Kang W, Kim M, Kim S, Park CK, Gastroenterology 2010 139 84 92 10.1053/j.gastro.2010.04.002 20398662
20. Immunotherapy for EBV-associated malignancies. Merlo A, Turrini R, Dolcetti R, Zanovello P, Rosato A, Int J Hematol 2011 93 281 293 10.1007/s12185-011-0782-2 21336546
21. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, et al. J Immunother 2010 33 983 990 10.1097/CJI.0b013e3181f3cbf4 20948438
22. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells. Kim YJ, Lim J, Kang JS, Kim HM, Lee HK, Ryu HS, Kim JY, Hong JT, Kim Y, Han SB, Arch Pharm Res 2010 33 1789 1795 10.1007/s12272-010-1111-7 21116782
23. Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells. Lundqvist A, Berg M, Smith A, Childs RW, J Cancer 2011 2 383 385 21750690
24. Epstein-Barr virus-associated gastric carcinoma. Fukayama M, Ushiku T, Pathol Res Pract 2011 207 529 537 10.1016/j.prp.2011.07.004 21944426
25. Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. Claerhout S, Lim JY, Choi W, Park YY, Kim K, Kim SB, Lee JS, Mills GB, Cho JY, PLoS One 2011 6 24662 10.1371/journal.pone.0024662 21931799
26. Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors. Daigle D, Megyola C, El-Guindy A, Gradoville L, Tuck D, Miller G, Bhaduri-McIntosh S, J Virol 2010 84 993 1004 10.1128/JVI.01745-09 19889776
27. Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells. Destro F, Sforza F, Sicurella M, Marescotti D, Gallerani E, Baldisserotto A, Marastoni M, Gavioli R, Immunology 2011 133 105 114 10.1111/j.1365-2567. 2011.03416.x 21342184
28. Bortezomib induction of C/EBPbeta mediates Epstein-Barr virus lytic activation in Burkitt lymphoma. Shirley CM, Chen J, Shamay M, Li H, Zahnow CA, Hayward SD, Ambinder RF, Blood 2011 117 6297 6303 10.1182/blood-2011-01-332379 21447826
29. Theodore E. Woodward Award: Development of Novel, EBV-Targeted Therapies for EBV-Positive Tumors. Kenney S, Trans Am Clin Climatol Assoc 2006 117 55 74 18528464
30. The control of lytic replication of Epstein-Barr virus in B lymphocytes (Review). Schwarzmann F, Jager M, Prang N, Wolf H, Int J Mol Med 1998 1 137 142 9852211
31. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. Laichalk LL, Thorley-Lawson DA, J Virol 2005 79 1296 1307 10.1128/JVI.79.2.1296-1307.2005 15613356 (Pubitemid 40053911)
32. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Feng WH, Kenney SC, Cancer Res 2006 66 8762 8769 10.1158/0008-5472.CAN-06-1006 16951192 (Pubitemid 44449193)
33. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. Hui KF, Chiang AK, Int J Cancer 2010 126 2479 2489 19816947
34. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Feng WH, Israel B, Raab-Traub N, Busson P, Kenney SC, Cancer Res 2002 62 1920 1926 11912175 (Pubitemid 34408523)
35. Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors. Feng WH, Westphal E, Mauser A, Raab-Traub N, Gulley ML, Busson P, Kenney SC, J Virol 2002 76 10951 10959 10.1128/JVI.76.21.10951-10959.2002 12368338 (Pubitemid 35176212)
36. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. Feng WH, Cohen JI, Fischer S, Li L, Sneller M, Goldbach-Mansky R, Raab-Traub N, Delecluse HJ, Kenney SC, J Natl Cancer Inst 2004 96 1691 1702 10.1093/jnci/djh313 15547182 (Pubitemid 39585638)
37. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. Feng WH, Hong G, Delecluse HJ, Kenney SC, J Virol 2004 78 1893 1902 10.1128/JVI.78.4.1893-1902.2004 14747554 (Pubitemid 38176721)
38. Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. Jones K, Nourse J, Corbett G, Gandhi MK, Int J Lab Hematol 2010 32 169 174 10.1111/j.1751-553X.2008.01130.x 19196381
39. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Westphal EM, Blackstock W, Feng W, Israel B, Kenney SC, Cancer Res 2000 60 5781 5788 11059774
40. Zinc finger E-box binding factor 1 plays a central role in regulating Epstein-Barr virus (EBV) latent-lytic switch and acts as a therapeutic target in EBV-associated gastric cancer. Zhao J, Jin H, Cheung KF, Tong JH, Zhang S, Go MY, Tian L, Kang W, Leung PP, Zeng Z, et al. Cancer 2012 118 924 936 10.1002/cncr.26184 21717425
41. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production. Meng Q, Hagemeier SR, Fingeroth JD, Gershburg E, Pagano JS, Kenney SC, J Virol 2010 84 4534 4542 10.1128/JVI.02487-09 20181711
42. Quality assurance of RNA expression profiling in clinical laboratories. Tang W, Hu Z, Muallem H, Gulley ML, J Mol Diagn 2012 14 1 11 10.1016/j.jmoldx.2011.09.003 22020152
43. mRNA transcript quantification in archival samples using multiplexed, color-coded probes. Reis PP, Waldron L, Goswami RS, Xu W, Xuan Y, Perez-Ordonez B, Gullane P, Irish J, Jurisica I, Kamel-Reid S, BMC Biotechnol 2011 11 46 10.1186/1472-6750-11-46 21549012
44. Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter Assay System. Malkov VA, Serikawa KA, Balantac N, Watters J, Geiss G, Mashadi-Hossein A, Fare T, BMC Res Notes 2009 2 80 10.1186/1756-0500-2-80 19426535
45. Digital multiplexed gene expression analysis using the NanoString nCounter system. Kulkarni MM, Curr Protoc Mol Biol 2011 Chapter 25: Unit 25B 10. [ http://onlinelibrary.wiley.com/doi/10.1002/0471142727.mb25b10s94/abstract ]
46. High levels of Epstein-Barr virus DNA in latently infected gastric adenocarcinoma. Ryan JL, Morgan DR, Dominguez RL, Thorne LB, Elmore SH, Mino-Kenudson M, Lauwers GY, Booker JK, Gulley ML, Lab Invest 2009 89 80 90 10.1038/labinvest.2008.103 19002111
47. Deep sequencing reveals direct targets of gammaherpesvirus-induced mRNA decay and suggests that multiple mechanisms govern cellular transcript escape. Clyde K, Glaunsinger BA, PLoS One 2011 6 19655 10.1371/journal.pone.0019655 21573023
48. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Imai S, Koizumi S, Sugiura M, Tokunaga M, Uemura Y, Yamamoto N, Tanaka S, Sato E, Osato T, Proc Natl Acad Sci U S A 1994 91 9131 9135 10.1073/pnas.91.19.9131 8090780
49. Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Sugiura M, Imai S, Tokunaga M, Koizumi S, Uchizawa M, Okamoto K, Osato T, Br J Cancer 1996 74 625 631 10.1038/bjc.1996.412 8761381 (Pubitemid 26279061)
50. Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas. Luo B, Wang Y, Wang XF, Liang H, Yan LP, Huang BH, Zhao P, World J Gastroenterol 2005 11 629 633 15655811 (Pubitemid 40220748)
51. Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. zur Hausen A, Brink AA, Craanen ME, Middeldorp JM, Meijer CJ, van den Brule AJ, Cancer Res 2000 60 2745 2748 10825150 (Pubitemid 30318253)
52. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Jeung HC, Rha SY, Im CK, Shin SJ, Ahn JB, Yang WI, Roh JK, Noh SH, Chung HC, Cancer 2011 117 2050 2057 10.1002/cncr.25729 21523716
53. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer. Cho YB, Chung HJ, Lee WY, Choi SH, Kim HC, Yun SH, Chun HK, Anticancer Res 2011 31 3843 3849 22110208
54. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Moore SM, Cannon JS, Tanhehco YC, Hamzeh FM, Ambinder RF, Antimicrob Agents Chemother 2001 45 2082 2091 10.1128/AAC.45.7.2082-2091.2001 11408227 (Pubitemid 32591702)
55. Transcriptome dissection of gastric cancer: identification of novel diagnostic and therapeutic targets from pathology specimens. Yasui W, Oue N, Sentani K, Sakamoto N, Motoshita J, Pathol Int 2009 59 121 136 10.1111/j.1440-1827.2009.02329.x 19261089
56. Gene expression profiling with microarray and SAGE identifies PLUNC as a marker for hepatoid adenocarcinoma of the stomach. Sentani K, Oue N, Sakamoto N, Arihiro K, Aoyagi K, Sasaki H, Yasui W, Mod Pathol 2008 21 464 475 10.1038/modpathol.3801050 18204429 (Pubitemid 351441036)
57. Identification of candidate molecular markers of nasopharyngeal carcinoma by microarray analysis of subtracted cDNA libraries constructed by suppression subtractive hybridization. Zhou Y, Zeng Z, Zhang W, Xiong W, Li X, Zhang B, Yi W, Xiao L, Wu M, Shen S, et al. Eur J Cancer Prev 2008 17 561 571 10.1097/CEJ.0b013e328305a0e8 18941378
58. Molecular cross-regulation between PPAR-gamma and other signaling pathways: implications for lung cancer therapy. Reka AK, Goswami MT, Krishnapuram R, Standiford TJ, Keshamouni VG, Lung Cancer 2011 72 154 159 10.1016/j.lungcan.2011.01.019 21354647
59. Epstein-Barr virus-associated gastric carcinoma: a distinct carcinoma of gastric phenotype by claudin expression profiling. Shinozaki A, Ushiku T, Morikawa T, Hino R, Sakatani T, Uozaki H, Fukayama M, J Histochem Cytochem 2009 57 775 785 10.1369/jhc.2009.953810 19398608
60. Genomic Loss of miR-486 Regulates Tumor Progression and the OLFM4 Antiapoptotic Factor in Gastric Cancer. Oh HK, Tan AL, Das K, Ooi CH, Deng NT, Tan IB, Beillard E, Lee J, Ramnarayanan K, Rha SY, et al. Clin Cancer Res 2011 17 2657 2667 10.1158/1078-0432.CCR-10-3152 21415212
61. Over-expression of Ephb4 is associated with carcinogenesis of gastric cancer. Li M, Zhao ZW, Zhang Y, Xin Y, Dig Dis Sci 2011 56 698 706 10.1007/s10620-010-1346-7 20686847
62. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, et al. Gastroenterology 2011 141 476 485 485 e471-411 10.1053/j.gastro.2011.04.042 21684283
63. REGIV as a potential biomarker for peritoneal dissemination in gastric adenocarcinoma. Moon JH, Fujiwara Y, Nakamura Y, Okada K, Hanada H, Sakakura C, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, et al. J Surg Oncol 2012 105 189 194 10.1002/jso.22021 21780125
64. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Patriarca C, Macchi RM, Marschner AK, Mellstedt H, Cancer Treat Rev 2012 38 68 75 10.1016/j.ctrv.2011.04.002 21576002
65. PPAR gamma, bioactive lipids, and cancer progression. Robbins GT, Nie D, Front Biosci 2012 17 1816 1834 10.2741/4021 22201838
66. Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Mitani Y, Oue N, Matsumura S, Yoshida K, Noguchi T, Ito M, Tanaka S, Kuniyasu H, Kamata N, Yasui W, Oncogene 2007 26 4383 4393 10.1038/sj.onc.1210215 17237819 (Pubitemid 47014457)
67. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. Choy EY, Siu KL, Kok KH, Lung RW, Tsang CM, To KF, Kwong DL, Tsao SW, Jin DY, J Exp Med 2008 205 2551 2560 10.1084/jem.20072581 18838543
68. A shared gene expression signature in mouse models of EBV-associated and non-EBV-associated Burkitt lymphoma. Bieging KT, Fish K, Bondada S, Longnecker R, Blood 2011 118 6849 6859 10.1182/blood-2011-02-338434 22039254
69. Field effect in cancer-an update. Chai H, Brown RE, Ann Clin Lab Sci 2009 39 331 337 19880759
70. Human tumor virus utilizes exosomes for intercellular communication. Meckes DG, Shair KH, Marquitz AR, Kung CP, Edwards RH, Raab-Traub N, Proc Natl Acad Sci U S A 2010 107 20370 20375 10.1073/pnas.1014194107 21059916
71. Microvesicles and viral infection. Meckes DG, Raab-Traub N, J Virol 2011 85 12844 12854 10.1128/JVI.05853-11 21976651
72. An integrated transcriptomic and computational analysis for biomarker identification in gastric cancer. Cui J, Chen Y, Chou WC, Sun L, Chen L, Suo J, Ni Z, Zhang M, Kong X, Hoffman LL, et al. Nucleic Acids Res 2011 39 1197 1207 10.1093/nar/gkq960 20965966
73. Distinctions in gastric cancer gene expression signatures derived from laser capture microdissection versus histologic macrodissection. Kim HK, Kim J, Korolevich S, Choi IJ, Kim CH, Munroe DJ, Green JE, BMC Med Genomics 2011 4 48 10.1186/1755-8794-4-48 21635755
74. An 8-gene signature, including methylated and down-regulated glutathione peroxidase 3, of gastric cancer. Zhang X, Yang JJ, Kim YS, Kim KY, Ahn WS, Yang S, Int J Oncol 2010 36 405 414 20043075
75. A comparative analysis of gene-expression data of multiple cancer types. Xu K, Cui J, Olman V, Yang Q, Puett D, Xu Y, PLoS One 2010 5 13696 10.1371/journal.pone.0013696 21060876
76. Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines. Junnila S, Kokkola A, Karjalainen- Lindsberg ML, Puolakkainen P, Monni O, BMC Cancer 2010 10 73 10.1186/1471-2407-10-73 20187983
77. Role of DNA methylation in the development of diffuse-type gastric cancer. Yamamoto E, Suzuki H, Takamaru H, Yamamoto H, Toyota M, Shinomura Y, Digestion 2011 83 241 249 10.1159/000320453 21273772
78. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, et al. J Med Genet 2010 47 436 444 10.1136/jmg.2009.074237 20591882
79. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. Niller HH, Wolf H, Minarovits J, Semin Cancer Biol 2009 19 158 164 10.1016/j.semcancer.2009.02.012 19429479
80. Epstein-Barr virus and gastric carcinoma. Osato T, Imai S, Semin Cancer Biol 1996 7 175 182 10.1006/scbi.1996.0024 8946601 (Pubitemid 26395119)
81. Gastric adenocarcinoma with differentiation to sarcomatous components associated with monoclonal Epstein-Barr virus infection and LMP-1 expression. Kida Y, Miyauchi K, Takano Y, Virchows Arch A Pathol Anat Histopathol 1993 423 383 387 10.1007/BF01607151 8116227 (Pubitemid 23345713)
82. Epstein-Barr Virus Infection Is Common in Inflamed Gastrointestinal Mucosa. Ryan JL, Shen YJ, Morgan DR, Thorne LB, Kenney SC, Dominguez RL, Gulley ML, Dig Dis Sci 2012
83. Epstein-Barr virus-specific antibodies in Epstein-Barr virus-positive and -negative gastric carcinoma cases in Japan. Shinkura R, Yamamoto N, Koriyama C, Shinmura Y, Eizuru Y, Tokunaga M, J Med Virol 2000 60 411 416 10.1002/(SICI)1096-9071(200004)60:4<411::AID-JMV8>3.0.CO;2-8 10686024 (Pubitemid 30127312)
84. Detection of lymphocytes productively infected with Epstein-Barr virus in non-neoplastic tonsils. Ikeda T, Kobayashi R, Horiuchi M, Nagata Y, Hasegawa M, Mizuno F, Hirai K, J Gen Virol 2000 81 1211 1216 10769062 (Pubitemid 30232705)
85. Epstein-Barr virus-specific methylation of human genes in gastric cancer cells. Ryan JL, Jones RJ, Kenney SC, Rivenbark AG, Tang W, Knight ER, Coleman WB, Gulley ML, Infect Agent Cancer 2010 5 27 10.1186/1750-9378-5-27 21194482
86. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Wang WY, Twu CW, Chen HH, Jan JS, Jiang RS, Chao JY, Liang KL, Chen KW, Wu CT, Lin JC, Clin Cancer Res 2010 16 1016 1024 10.1158/1078-0432.CCR-09-2796 20103659
87. Detection of Epstein-Barr Virus DNA in Serum or Plasma for Nasopharyngeal Cancer: A Meta-Analysis. Liu Y, Fang Z, Liu L, Yang S, Zhang L, Genet Test Mol Biomarkers 2011 45 1292 1294
88. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Gulley ML, Tang W, Clin Microbiol Rev 2010 23 350 366 10.1128/CMR.00006-09 20375356
89. Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. Lo KW, Lo YM, Leung SF, Tsang YS, Chan LY, Johnson PJ, Hjelm NM, Lee JC, Huang DP, Clin Chem 1999 45 1292 1294 10430801 (Pubitemid 29424274)
90. T cell therapy for nasopharyngeal carcinoma. Basso S, Zecca M, Merli P, Gurrado A, Secondino S, Quartuccio G, Guido I, Guerini P, Ottonello G, Zavras N, et al. J Cancer 2011 2 341 346 21716854
91. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Sili U, Leen AM, Vera JF, Gee AP, Huls H, Heslop HE, Bollard CM, Rooney CM, Cytotherapy 2012 14 7 11 10.3109/14653249.2011.636963 22172091
92. Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells. Iwata S, Saito T, Ito Y, Kamakura M, Gotoh K, Kawada J, Nishiyama Y, Kimura H, Cancer Sci 2012 103 375 381 10.1111/j.1349-7006.2011.02127.x 22017376
93. Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies. Ghosh SK, Perrine SP, Faller DV, Adv Virol 2012 2012 509296 22500168
94. Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. Ryan JL, Fan H, Glaser SL, Schichman SA, Raab-Traub N, Gulley ML, J Mol Diagn 2004 6 378 385 10.1016/S1525-1578(10)60535-1 15507678 (Pubitemid 39517407)
95. Automated in situ hybridization and immunohistochemistry for cytomegalovirus detection in paraffin-embedded tissue sections. Lu DY, Qian J, Easley KA, Waldrop SM, Cohen C, Appl Immunohistochem Mol Morphol 2009 17 158 164 10.1097/PAI.0b013e318185d1b5 19521278